Clinical trials: HCM
Hypertrophic Cardiomyopathy
Genetic Predictors of Outcome in HCM Patients
This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies.
- Trial name
- NCT00156429
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of Pittsburgh
Ischemic Cardiomyopathy, Dilated Cardiomyopathy
Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein…
- Conditions
- Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
- Trial name
- NCT03607669
- Testing
- Mangafodipir trisodium
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Hypertrophic Cardiomyopathy (HCM)
Evaluation of Clinical Efficacy and Prognosis in Patients With Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT
Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant inherited heart disease, with previous data suggesting a prevalence of approximately 1 in 500 in the population.
- Trial name
- NCT06683872
- Testing
- surgical myectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Provincial People's Hospital
Hypertrophic Cardiomyopathy
Austrian Hypertrophic Cardiomyopathy Registry
The Austrian Hypertrophic Cardiomyopathy (HCM) Registry is a prospective, multicenter registry enrolling patients at multiple outpatient clinics across Austria including academic and non-academic centers.
- Trial name
- NCT06368518
- Where
- 15 sites in Austria
- Volunteers
- 1,000 people
- Sponsor
- Medical University of Graz
Cardiopulmonary Exercise Test, Hypertrophic Cardiomyopathy
Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy
Fatigue and dyspnea that reduce exercise performance are common symptoms in patients with hypertrophic cardiomyopathy. Since the cause of this functional limitation has not yet been described, this study aims to evaluate the…
- Conditions
- Cardiopulmonary Exercise Test, Hypertrophic Cardiomyopathy, Cardiac Output Measurement
- Trial name
- NCT05754489
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Centro Cardiologico Monzino
Cardiomyopathy, Hypertrophic, Familial
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease
Genetically inherited heart diseases (familial cardiomyopathies) are conditions affecting the heart passed on to family members through abnormalities in genetic information.
- Trial name
- NCT00001881
- Where
- United States
- Volunteers
- 9,999 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common genetic cardiomyopathy and remains the leading cause of sudden cardiac death in young people and an important cause of heart failure symptoms and death at any age.
- Trial name
- NCT00879060
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Cardiac Rehabilitation
"Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy".
Hypertrophic cardiomyopathy (HCM) is the most common hereditary disease characterized by left ventricular hypertrophy and consequently left ventricular diastolic dysfunction.
- Trial name
- NCT03178357
- Testing
- Cardiac rehabilitation + standard therapy, Standard therapy
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance.
- Trial name
- NCT05135871
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- LianBio LLC
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Septal Ablation for Obstructive HCM
Hypertrophic cardiomyopathy (HCM) is a common clinical genetic-related disease, with a global incidence of 0.2%-0.5%, but only a few cases (10-20%) have been clinically diagnosed.
- Trial name
- NCT06277960
- Testing
- percutaneous intramyocardial septal radiofrequency ablation system
- Where
- China
- Volunteers
- 20 people
- Sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
- Trial name
- SONATA-HCM (NCT06481891)
- Testing
- Sotagliflozin
- Where
- 108 sites in United States, Argentina and 17 more
- Volunteers
- 500 people
- Sponsor
- Lexicon Pharmaceuticals
Danon Disease
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (rAAV9) vector containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B)…
- Trial name
- NCT06092034
- Testing
- RP-A501
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 18 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Cardiovascular Disease (CVD), Heart Failure
Study of the Progression of Chronic Cardiovascular Conditions
This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.
- Conditions
- Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease
- Trial name
- OCORO (NCT07420907)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Prolaio
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
This study will examine the effectiveness of the drug cyclosporine in treating hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens.
- Trial name
- NCT00001965
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with…
- Trial name
- NCT06347159
- Testing
- EDG-7500
- Where
- 21 sites in United States
- Volunteers
- 79 people
- Sponsor
- Edgewise Therapeutics, Inc.
Aortic Stenosis, Disorder of Prosthetic Cardiac Valve
Biomarkers in Aortic Stenosis - B.A.S.S.
This study is being done to determine whether or not new blood test(s) can determine the severity of heart conditions. Aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, aortic regurgitation, artificial heart…
- Conditions
- Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency
- Trial name
- BASS (NCT01334801)
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hypertrophic Cardiomyopathy (HCM), Heart Failure
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)
RASopathy-associated hypertrophic cardiomyopathy (RAS-CM) is a disease with high morbidity and high mortality if presenting during infancy.
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Heart Failure, RASopathy
- Trial name
- RAS-CM (NCT07344480)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Nonobstructive Hypertrophic Cardiomyopathy
Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of dapagliflozin in patients with nonobstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- DAPA-HCM (NCT07897500)
- Testing
- Dapagliflozin 10mg
- Volunteers
- 440 people
- Sponsor
- Yonsei University
Cardiomyopathy, Hypertrophic
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [New York…
- Trial name
- MEMENTO (NCT06112743)
- Testing
- Mavacamten
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 63 people
- Sponsor
- Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy, Mavacamten
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM).
- Conditions
- Obstructive Hypertrophic Cardiomyopathy, Mavacamten, Radiofrequency Ablation
- Trial name
- NCT06856265
- Testing
- radiofrequency ablation, Mavacamten
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital